You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 28, 2024

~ Buy the XENOVIEW (xenon xe-129 hyperpolarized) Drug Profile, 2024 PDF Report in the Report Store ~

XENOVIEW Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Xenoview patents expire, and when can generic versions of Xenoview launch?

Xenoview is a drug marketed by Polarean and is included in one NDA. There are two patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in XENOVIEW is xenon xe-129 hyperpolarized. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the xenon xe-129 hyperpolarized profile page.

DrugPatentWatch® Generic Entry Outlook for Xenoview

Xenoview will be eligible for patent challenges on December 23, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 23, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for XENOVIEW
International Patents:6
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 9
Patent Applications: 81
What excipients (inactive ingredients) are in XENOVIEW?XENOVIEW excipients list
DailyMed Link:XENOVIEW at DailyMed
Drug patent expirations by year for XENOVIEW
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for XENOVIEW
Generic Entry Date for XENOVIEW*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
GAS;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for XENOVIEW

US Patents and Regulatory Information for XENOVIEW

XENOVIEW is protected by two US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of XENOVIEW is ⤷  Try a Trial.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting XENOVIEW

Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting XENOVIEW

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Polarean XENOVIEW xenon xe-129 hyperpolarized GAS;INHALATION 214375-001 Dec 23, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Polarean XENOVIEW xenon xe-129 hyperpolarized GAS;INHALATION 214375-001 Dec 23, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Polarean XENOVIEW xenon xe-129 hyperpolarized GAS;INHALATION 214375-001 Dec 23, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for XENOVIEW

See the table below for patents covering XENOVIEW around the world.

Country Patent Number Title Estimated Expiration
Canada 2940109 SYSTEMES DE PRODUCTION DE GAZ NOBLES HYPERPOLARISES AVEC ELIMINATION, DETECTION ET/OU FILTRATION DE NANOAGREGATS ET PROCEDES ET DISPOSITIFS ASSOCIES (HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES) ⤷  Try a Trial
Hungary E045999 ⤷  Try a Trial
China 106456808 具有纳米簇抑制、检测和/或过滤的超偏振稀有气体生产系统及相关的方法和装置 (Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices) ⤷  Try a Trial
Australia 2015218883 Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2015127208 ⤷  Try a Trial
European Patent Office 3107583 SYSTÈMES DE PRODUCTION DE GAZ NOBLES HYPERPOLARISÉS AVEC ÉLIMINATION, DÉTECTION ET/OU FILTRATION DE NANOAGRÉGATS ET PROCÉDÉS ET DISPOSITIFS ASSOCIÉS (HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.